|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Sakashita S, Sakashita M and Tsao Sound M:
Genes and pathology of non-small cell lung carcinoma. Semin Oncol.
41:28–39. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hu P, He J, Liu S, Wang M, Pan B and Zhang
W: beta2-adrenergic receptor activation promotes the proliferation
of A549 lung cancer cells via the ERK1/2/CREB pathway. Oncol Rep.
36:1757–1763. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Youlden DR, Cramb SM and Baade PD: The
international epidemiology of lung cancer: Geographical
distribution and secular trends. J Thorac Oncol. 3:819–831. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Efferth T, Li PC, Konkimalla VS and Kaina
B: From traditional Chinese medicine to rational cancer therapy.
Trends Mol Med. 13:353–361. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Tan W, Lu J, Huang M, Li Y, Chen M, Wu G,
Gong J, Zhong Z, Xu Z, Dang Y, et al: Anticancer natural products
isolated from chinese medicinal herbs. Chin Med. 6:272011.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Singla AK, Garg A and Aggarwal D:
Paclitaxel and its formulations. Int J Pharm. 235:179–192. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wu CY, Cherng JY, Yang YH, Lin CL, Kuan
FC, Lin YY, Lin YS, Shu LH, Cheng YC, Liu HT, et al: Danshen
improves survival of patients with advanced lung cancer and
targeting the relationship between macrophages and lung cancer
cells. Oncotarget. 8:90925–90947. 2017.PubMed/NCBI
|
|
9
|
Chen X, Guo J, Bao J, Lu J and Wang Y: The
anticancer properties of Salvia miltiorrhiza Bunge
(Danshen): A systematic review. Med Res Rev. 34:768–794. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Shin DS, Kim HN, Shin KD, Yoon YJ, Kim SJ,
Han DC and Kwon BM: Cryptotanshinone inhibits constitutive signal
transducer and activator of transcription 3 function through
blocking the dimerization in DU145 prostate cancer cells. Cancer
Res. 69:193–202. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kim JH, Jeong SJ, Kwon TR, Yun SM, Jung
JH, Kim M, Lee HJ, Lee MH, Ko SG, Chen CY, et al: Cryptotanshinone
enhances TNF-alpha-induced apoptosis in chronic myeloid leukemia
KBM-5 cells. Apoptosis. 16:696–707. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lu L, Li C, Li D, Wang Y, Zhou C, Shao W,
Peng J, You Y, Zhang X and Shen X: Cryptotanshinone inhibits human
glioma cell proliferation by suppressing STAT3 signaling. Mol Cell
Biochem. 381:273–282. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Park IJ, Yang WK, Nam SH, Hong J, Yang KR,
Kim J, Kim SS, Choe W, Kang I and Ha J: Cryptotanshinone induces G1
cell cycle arrest and autophagic cell death by activating the
AMP-activated protein kinase signal pathway in HepG2 hepatoma.
Apoptosis. 19:615–628. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ge Y, Yang B, Chen Z and Cheng R:
Cryptotanshinone suppresses the proliferation and induces the
apoptosis of pancreatic cancer cells via the STAT3 signaling
pathway. Mol Med Rep. 12:7782–7788. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Li S, Wang H, Hong L, Liu W, Huang F, Wang
J, Wang P, Zhang X and Zhou J: Cryptotanshinone inhibits breast
cancer cell growth by suppressing estrogen receptor signaling.
Cancer Biol Ther. 16:176–184. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Li W, Saud SM, Young MR, Colburn NH and
Hua B: Cryptotanshinone, a Stat3 inhibitor, suppresses colorectal
cancer proliferation and growth in vitro. Mol Cell Biochem.
406:63–73. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ye T, Zhu S, Zhu Y, Feng Q, He B, Xiong Y,
Zhao L, Zhang Y, Yu L and Yang L: Cryptotanshinone induces melanoma
cancer cells apoptosis via ROS-mitochondrial apoptotic pathway and
impairs cell migration and invasion. Biomed Pharmacother.
82:319–326. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Werner H and Bruchim I: The insulin-like
growth factor-I receptor as an oncogene. Arch Physiol Biochem.
115:58–71. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Resnik JL, Reichart DB, Huey K, Webster NJ
and Seely BL: Elevated insulin-like growth factor I receptor
autophosphorylation and kinase activity in human breast cancer.
Cancer Res. 58:1159–1164. 1998.PubMed/NCBI
|
|
20
|
Weber MM, Fottner C, Liu SB, Jung MC,
Engelhardt D and Baretton GB: Overexpression of the insulin-like
growth factor I receptor in human colon carcinomas. Cancer.
95:2086–2095. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Sharon C, Baranwal S, Patel NJ,
Rodriguez-Agudo D, Pandak WM, Majumdar AP, Krystal G and Patel BB:
Inhibition of insulin-like growth factor receptor/AKT/mammalian
target of rapamycin axis targets colorectal cancer stem cells by
attenuating mevalonate-isoprenoid pathway in vitro and in vivo.
Oncotarget. 6:15332–15347. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Teng JA, Wu SG, Chen JX, Li Q, Peng F, Zhu
Z, Qin J and He ZY: The activation of ERK1/2 and JNK MAPK signaling
by insulin/IGF-1 is responsible for the development of colon cancer
with type 2 diabetes mellitus. PLoS One. 11:e01498222016.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhou Y, Zeng C, Li X, Wu PL, Yin L, Yu XL,
Zhou YF and Xue Q: IGF-I stimulates ERbeta and aromatase expression
via IGF1R/PI3K/AKT-mediated transcriptional activation in
endometriosis. J Mol Med. 94:887–897. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hennessy BT, Smith DL, Ram PT, Lu Y and
Mills GB: Exploiting the PI3K/AKT pathway for cancer drug
discovery. Nat Rev Drug Discov. 4:988–1004. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kim WY, Jin Q, Oh SH, Kim ES, Yang YJ, Lee
DH, Feng L, Behrens C, Prudkin L, Miller YE, et al: Elevated
epithelial insulin-like growth factor expression is a risk factor
for lung cancer development. Cancer Res. 69:7439–7448. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kim WY, Prudkin L, Feng L, Kim ES,
Hennessy B, Lee JS, Lee JJ, Glisson B, Lippman SM, Wistuba II, et
al: Epidermal growth factor receptor and K-Ras mutations and
resistance of lung cancer to insulin-like growth factor 1 receptor
tyrosine kinase inhibitors. Cancer. 118:3993–4003. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Chen L, Wang HJ, Xie W, Yao Y, Zhang YS
and Wang H: Cryptotanshinone inhibits lung tumorigenesis and
induces apoptosis in cancer cells in vitro and in vivo. Mol Med
Rep. 9:2447–2452. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Peled N, Wynes MW, Ikeda N, Ohira T,
Yoshida K, Qian J, Ilouze M, Brenner R, Kato Y, Mascaux C, et al:
Insulin-like growth factor-1 receptor (IGF-1R) as a biomarker for
resistance to the tyrosine kinase inhibitor gefitinib in non-small
cell lung cancer. Cell Oncol. 36:277–288. 2013. View Article : Google Scholar
|
|
29
|
Engelman JA: Targeting PI3K signalling in
cancer: Opportunities, challenges and limitations. Nat Rev Cancer.
9:550–562. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
30
|
Thorpe LM, Yuzugullu H and Zhao JJ: PI3K
in cancer: Divergent roles of isoforms, modes of activation and
therapeutic targeting. Nat Rev Cancer. 15:7–24. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Sun CH, Chang YH and Pan CC: Activation of
the PI3K/Akt/mTOR pathway correlates with tumour progression and
reduced survival in patients with urothelial carcinoma of the
urinary bladder. Histopathology. 58:1054–1063. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Luo J, Manning BD and Cantley LC:
Targeting the PI3K-Akt pathway in human cancer: Rationale and
promise. Cancer Cell. 4:257–262. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Kelly PN and Strasser A: The role of Bcl-2
and its pro-survival relatives in tumourigenesis and cancer
therapy. Cell Death Differ. 18:1414–1424. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
LeRoith D and Roberts CT Jr: The
insulin-like growth factor system and cancer. Cancer Lett.
195:127–137. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
De Luca A, Maiello MR, D'Alessio A,
Pergameno M and Normanno N: The RAS/RAF/MEK/ERK and the PI3K/AKT
signalling pathways: Role in cancer pathogenesis and implications
for therapeutic approaches. Expert Opin Ther Targets. 16 Suppl
2:S17–S27. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Datta SR, Dudek H, Tao X, Masters S, Fu H,
Gotoh Y and Greenberg ME: Akt phosphorylation of BAD couples
survival signals to the cell-intrinsic death machinery. Cell.
91:231–241. 1997. View Article : Google Scholar : PubMed/NCBI
|
